发明名称 CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
摘要 The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
申请公布号 US2016090417(A1) 申请公布日期 2016.03.31
申请号 US201514950748 申请日期 2015.11.24
申请人 Bristol-Myers Squibb Company 发明人 COGSWELL JOHN P.;Goldberg Stacie M.;Gupta Ashok K.;Jure-Kunkel Maria;Wang Xi-Tao;Wigginton Jon M.
分类号 C07K16/28;G01N33/574 主分类号 C07K16/28
代理机构 代理人
主权项
地址 Princeton NJ US